Skip to main content
Top
Published in: Journal of Robotic Surgery 3/2019

01-06-2019 | Original Article

Intraoperative mannitol during robotic-assisted-laparoscopic partial nephrectomy

Authors: Kellen Choi, Sharon Hill, Nathan Hale, Stephen Phillips, Samuel Deem

Published in: Journal of Robotic Surgery | Issue 3/2019

Login to get access

Abstract

Mannitol is routinely used during partial nephrectomies due to its renoprotective properties. With minimally invasive techniques, the need for mannitol has been questioned. Robotic-assisted laparoscopic partial nephrectomy (RALPN) has been shown to decrease warm ischemia time, which may potentially minimize the benefit of mannitol. To date, no prospective, randomized, controlled trials have investigated the use of mannitol in only robotic procedures. We hypothesize that the intraoperative mannitol use during RALPN provides no statistically significant benefit for post-operative renal function outcomes. We conducted a randomized, controlled, double-blinded, single surgeon, prospective study to assess renal function after RALPN. Patients were randomized into a control group with intravenous normal saline infusion prior to clamping of the vessels or to an experimental group with an infusion of mannitol. Estimated glomerular filtration rate (eGFR) were obtained prior to the surgery as well as post operatively at 24 h, 1 week, and 30 days. Preoperative eGFR showed no statistical differences between the groups and evaluation of median percent change in eGFR after surgery did not indicate a statistical difference between the groups after RALPN. After prospective analysis of the change in post-operative renal function of randomized groups who received 12 g of mannitol following RALPN, we determined that infusion of mannitol does not provide significant improvement of maintenance of renal functions after RALPN. Based on our results, we recommend discontinuing routine use of mannitol during RALPN.
Literature
3.
go back to reference Chow W, Devesa SS, Warren JL et al (1999) Rising incidence of renal cell carcinoma in the United States. JAMA 281:1628CrossRefPubMed Chow W, Devesa SS, Warren JL et al (1999) Rising incidence of renal cell carcinoma in the United States. JAMA 281:1628CrossRefPubMed
4.
go back to reference Nicholas E, Power AC, Maschino et al (2012) Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. Urology 79(4):821–825CrossRef Nicholas E, Power AC, Maschino et al (2012) Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. Urology 79(4):821–825CrossRef
5.
go back to reference Volpe A, Cadeddu JA et al (2011) Contemporary management of small renal masses. Eur Urol 60(3):501–515CrossRefPubMed Volpe A, Cadeddu JA et al (2011) Contemporary management of small renal masses. Eur Urol 60(3):501–515CrossRefPubMed
6.
go back to reference Cosentino M, Breda A et al (2012) The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol 31:977–982 Cosentino M, Breda A et al (2012) The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol 31:977–982
7.
go back to reference Visweswaran P, Massin EK, Dubose TD Jr (1997) Mannitol-induced acute renal failure. J Am Soc Nephrol 8(6):1028–1033PubMed Visweswaran P, Massin EK, Dubose TD Jr (1997) Mannitol-induced acute renal failure. J Am Soc Nephrol 8(6):1028–1033PubMed
8.
go back to reference Gelman S (1996) Does mannitol save the kidney? Anesth Analg 82(5):899–901PubMed Gelman S (1996) Does mannitol save the kidney? Anesth Analg 82(5):899–901PubMed
9.
go back to reference Hemmelgarn BR et al (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303(5):423CrossRefPubMed Hemmelgarn BR et al (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303(5):423CrossRefPubMed
10.
go back to reference Spaliviero M, Power NE, Murray KS et al (2018) Intravenous mannitol versus placebo during partial nephrectomy in patients with normal kidney function: a double-blind, clinically-integrated, randomized trial. Eur Urol 73:53–59CrossRefPubMed Spaliviero M, Power NE, Murray KS et al (2018) Intravenous mannitol versus placebo during partial nephrectomy in patients with normal kidney function: a double-blind, clinically-integrated, randomized trial. Eur Urol 73:53–59CrossRefPubMed
12.
go back to reference Joannidis M, Druml W, Forni LG et al (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. Intensive Care Med 36:392CrossRefPubMed Joannidis M, Druml W, Forni LG et al (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. Intensive Care Med 36:392CrossRefPubMed
13.
go back to reference Collins GM, Green RD, Boyer D, Halasz NA (1980) Protection of kidneys from warm ischemic injury. Dosage and timing of mannitol administration. Transplantation 29:83–84CrossRefPubMed Collins GM, Green RD, Boyer D, Halasz NA (1980) Protection of kidneys from warm ischemic injury. Dosage and timing of mannitol administration. Transplantation 29:83–84CrossRefPubMed
Metadata
Title
Intraoperative mannitol during robotic-assisted-laparoscopic partial nephrectomy
Authors
Kellen Choi
Sharon Hill
Nathan Hale
Stephen Phillips
Samuel Deem
Publication date
01-06-2019
Publisher
Springer London
Published in
Journal of Robotic Surgery / Issue 3/2019
Print ISSN: 1863-2483
Electronic ISSN: 1863-2491
DOI
https://doi.org/10.1007/s11701-018-0868-4

Other articles of this Issue 3/2019

Journal of Robotic Surgery 3/2019 Go to the issue